{"id":450,"date":"2019-05-08T15:57:41","date_gmt":"2019-05-08T13:57:41","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=450"},"modified":"2024-04-11T08:11:01","modified_gmt":"2024-04-11T06:11:01","slug":"colorectal-cancer-2","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/cancer-area\/molecular-mechanisms-and-experimental-therapy-in-oncology-program-oncobell\/colorectal-cancer-2\/","title":{"rendered":"Colorectal Cancer"},"content":{"rendered":"\n

\n\t\tColorectal Cancer\n\t<\/h1>\n

\n\t\tSummary\n\t<\/h3>\n\t

The Colorectal Cancer (CRC) research group, led by V\u00edctor Moreno and Ramon Salazar, is focussed on discovering and validating new molecular signatures for diagnosis, prognosis and prediction, and identifying and optimising new therapeutic targets and molecular classifications of CRC, using an integromics approach, combining knowledge of genetic epidemiology, data bioinformatics and pharmacology.<\/p>\n

2760<\/h2>\n

Publications<\/h2>\n\t\t\t\t\"colorectal_adenocarcinoma_cytology_intermed_mag\n\t\t\t\t\tStrategic lines<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tMolecular characterisation of gastrointestinal tumours through genomic, transcriptomic and proteomic analysis (R. Salazar, V. Moreno).
\nConstruction of molecular signatures for predicting colorectal cancer prognosis (R. Salazar).
\nPredictions of therapeutic response based on molecular tumour detection and subtype classification (R. Salazar)
\nNew experimental therapeutic strategies to overcome resistance in colorectal cancer treatment (R. Salazar).
\nResearch, evaluation and validation of new diagnostic biomarkers in colorectal cancer (V. Moreno).
\nGenetic and epigenetic determinants of susceptibility to CRC and chemotherapy toxicity (V. Moreno).
\nImprovement in cancer precision medication and biomarker identification using computational analysis and large-scale integration of molecular data. (X. Sol\u00e9).
\nStratification of CRC patients based on molecular characteristics and the level of immune-cell infiltration of their tumours (C. Santos andR. Sanz-Pamplona).
\nMicrobiome-host interactions and colorectal cancer (V. Pimenoff, M. Obon, V. Moreno).
\nPrognostic and predictive values of circulating tumour DNA in metastatic colorectal cancer (C. Santos).\n\t\t\t\t\t
Selected Publications<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

Pinato DJ, Aguilar Company J, Ferrante D, Hanbury G, Bower M, Salazar R, Mirallas O, Sureda A, Plaja A, Cucurull M, Mesia R, Townsend S, Jackson A, Dalla Pria A, Newsom Davis T, Handford J, Sita Lumsden A, Apthorp E, Vincenzi B, Bertuzzi A, Brunet J, Lambertini M, Maluquer C, Pedrazzoli P, Biello F, Sinclair A, Bawany S, Khalique S, Rossi S, Rogers L, Murphy C, Belessiotis K, Carmona Garc\u00eda MC, Sharkey R, Garc\u00eda Illescas D, Rizzo G, Perachino M, Saoudi Gonzalez N, Doonga K, Fox L, Rold\u00e1n E, Gaidano G, Ruiz Camps I, Bruna R, Patriarca A, Martinez Vila C, Cantini L, Zambelli A, Giusti R, Mazzoni F, Caliman E, Santoro A, Grosso F, Parisi A, Queirolo P, Aujayeb A, Rimassa L, Prat A, Tucci M, Libertini M, Grisanti S, Mukherjee U, Diamantis N, Fusco V, Generali D, Provenzano S, Gennari A, Tabernero J, Cortellini A, OnCovid study G. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study<\/strong>. Lancet Oncol. 2022;23(7):865-875. doi:10.1016\/S1470-2045(22)00273-X.<\/p>\n

Jimenez Fonseca P, Salazar R, Valenti V, Msaouel P, Carmona Bayonas A. Is short-course radiotherapy and total neoadjuvant therapy the new standard of care in locally advanced rectal cancer? A sensitivity analysis of the RAPIDO clinical trial<\/strong>. Ann. Oncol. 2022;33(8):786-793. doi:10.1016\/j.annonc.2022.04.010.<\/p>\n

Olivera I, Sanz Pamplona R, Bolanos E, Rodriguez I, Etxeberria I, Cirella A, Egea J, Garasa S, Migueliz I, Eguren Santamaria I, Sanmamed MF, Glez Vaz J, Azpilikueta A, Alvarez M, Ochoa MC, Malacrida B, Propper D, de Andrea CE, Berraondo P, Balkwill FR, Teijeira A, Melero I. A therapeutically actionable pro-tumoral axis of cytokines involving interleukin-8, TNFa and IL-1B<\/strong>. Cancer Discov. 2022;12(9):2140-2157. doi:10.1158\/2159-8290.CD-21-1115.<\/p>\n

OnCovid Study G, Pinato DJ, Patel M, Scotti L, Colomba E, Dolly S, Loizidou A, Chester J, Mukherjee U, Zambelli A, Dalla Pria A, Aguilar Company J, Bower M, Salazar R, Bertuzzi A, Brunet J, Lambertini M, Tagliamento M, Pous A, Sita Lumsden A, Srikandarajah K, Colomba J, Pommeret F, Segu\u00ed E, Generali D, Grisanti S, Pedrazzoli P, Rizzo G, Libertini M, Moss C, Evans JS, Russell B, Harbeck N, Vincenzi B, Biello F, Bertulli R, Ottaviani D, Li\u00f1an R, Rossi S, Carmona Garc\u00eda MC, Tondini C, Fox L, Baggi A, Fotia V, Parisi A, Porzio G, Queirolo P, Cruz CA, Saoudi Gonzalez N, Felip E, Roqu\u00e9 Lloveras A, Newsom Davis T, Sharkey R, Rold\u00e1n E, Reyes R, Zoratto F, Earnshaw I, Ferrante D, Marco Hern\u00e1ndez J, Ruiz Camps I, Gaidano G, Patriarca A, Bruna R, Sureda A, Martinez Vila C, Sanchez de Torre A, Berardi R, Giusti R, Mazzoni F, Guida A, Rimassa L, Chiudinelli L, Franchi M, Krengli M, Santoro A, Prat A, Tabernero J, Van Hemelrijck M, Diamantis N, Gennari A, Cortellini A. Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry<\/strong>. JAMA Oncol. 2022;8(1):114-122. doi:10.1001\/jamaoncol.2021.6199.<\/p>\n

Herpers B, Eppink B, James MI, Cortina C, Ca\u00f1ellas Socias A, Boj SF, Hernando Momblona X, Glodzik D, Roovers RC, van de Wetering M, Bartelink Clements C, Zondag van der Zande V, Mateos JG, Yan K, Salinaro L, Basmeleh A, Fatrai S, Maussang D, Lammerts van Bueren JJ, Chicote I, Serna G, Cabellos L, Ram\u00edrez L, Nuciforo P, Salazar R, Santos C, Villanueva A, Stephan Otto Attolini C, Sancho E, Palmer HG, Tabernero J, Stratton MR, de Kruif J, Logtenberg T, Clevers H, Price LS, Vries RGJ, Batlle E, Throsby M. Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR \u00d7 LGR5 bispecific antibody with efficacy in epithelial tumors<\/strong>. Nat. Cancer. 2022;3(4):418-436. doi:10.1038\/s43018-022-00359-0.<\/p>\n\t\t\t\t\tSelected Projects<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

FIS22041. Understanding TIL composition and anti-tumor rEactivity in liver metastases from colorectal cancer patients (u-TIL-e )<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 130680. 2023-2025. PI: Salazar Soler, Ram\u00f3n \/ Losa Gasp\u00e0 Ferran.<\/p>\n

18INT006. ACRCelerate: Colorectal Cancer Stratified Medicine Network<\/strong>. WORLD CANCER RESEARCH FUND INTERNATIONAL WCRFI. Budget: 78756,34. 2018-2023. PI: Salazar Soler, Ram\u00f3n.<\/p>\n

21FIS026. \u00bfC\u00f3mo influye el microambiente inmune en el patr\u00f3n de diseminaci\u00f3n metast\u00e1sica y supervivencia en<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 123420. 2021-2023. PI: Santos Vivas, Cristina.<\/p>\n

18FIS005. Estudio de las interacciones microbioma-anfitri\u00f3n para la prevenci\u00f3n del c\u00e1ncer colorrectal (Colonbiome)<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 202070. 2018-2022. PI: Moreno Aguado, V\u00edctor; Pimenoff, Ville Nikolai.<\/p>\n

21ACL057. AN OPEN-LABEL STUDY OF THE EFFECT OF TESETAXEL ON THE QTC INTERVAL AND THE EFFECT OF FOOD, ITRACONAZOLE, AND RIFAMPIN ON TESETAXEL PHARMACOKINETICS IN PATIENTS WITH ADVANCED SOLID TUMORS<\/strong>. Budget: 178620. 2021- . PI: Mulet Margalef, N\u00faria.<\/p>\n\t\t\t\t\tMore Information<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tParticipation in international consortiums: MOTRICOLOR (Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer) and FIGI (Using functional genomics to inform gene environment interactions for CRC).
\nColonomics as a platform for biomarker discovery and characterisation of CRC.
\nClinical validation of ColoPrint\u00ae, a phase II prognostic genetic signature and new consensus on molecular subtype classification (CMS 1-4)\n\t\t\t\t\"Moreno\n

\n\t\tMoreno Aguado, Victor Raul\n\t<\/h4>\n

\n\t\t\n\t\tvmoreno@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Salazar\n

\n\t\tSalazar Soler, Ramon\n\t<\/h4>\n

\n\t\t\n\t\trsalazar@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tPrincipal investigators\n\t<\/h2>\n\t\t\t\t\"Moreno\n

\n\t\tMoreno Aguado, Victor Raul\n\t<\/h4>\n

\n\t\t\n\t\tvmoreno@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Salazar\n

\n\t\tSalazar Soler, Ramon\n\t<\/h4>\n

\n\t\t\n\t\trsalazar@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"avatar_idibell_0\"\n

\n\t\tSoler Gonz\u00e1lez, Gemma\n\t<\/h4>\n

\n\t\t\n\t\tgsolerg@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Eric-Duell\"\n

\n\t\tDuell, Eric\n\t<\/h4>\n

\n\t\t\n\t\teduell@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Cristina-Santos\"\n

\n\t\tSantos Vivas, Cristina\n\t<\/h4>\n

\n\t\t\n\t\tcsantos@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"avatar_idibell_0\"\n

\n\t\tMartinez Villacampa, Mercedes\n\t<\/h4>\n

\n\t\t\n\t\tmmartinezv@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tRELATED LINKS\n\t<\/h4>\n

\n\t\t\n\t\tColonomics\n\t\t<\/a>\n\t<\/h4>\n

\n\t\t\n\t\tMotricolor\n\t\t<\/a>\n\t<\/h4>\n

\n\t\t\n\t\tColscreen study\n\t\t<\/a>\n\t<\/h4>\n

\n\t\t\n\t\t@RamonSalazarS\n\t\t<\/a>\n\t<\/h4>\n

\n\t\t\n\t\t@PamplonaSanz\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tTeam\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tGroup leaders\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPrincipal investigators\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tClinical researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPostdoctoral researchers \t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPredoctoral researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tScientific support\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tManagement support\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tCollaborators\t\t\t\t<\/a>\n\t\t\t\t\t\tGroup leaders\n\t\t\t\t\t\t\t\t\t\t\t